Last 42 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.77 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 653.30 | 18.16 | 22.18 | 38.87 | 62.25 | 106.31 | 1036.64 | 22581.89 | 5333.60 | 2567.85 | 7415.42 | 541.43 | 7008.47 |
| — | -82.9% | -97.9% | -99.8% | -98.8% | -95.9% | -86.0% | +4070.8% | -23.9% | -39.0% | -29.9% | -98.6% | +352.8% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
ImmunityBio, Inc.'s operating margin was -173.5% in Q3 2025, up 96.3 pp QoQ and up 1140.8 pp YoY. This marks the 7th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -438.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 12.9% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 87.1% | 99.5% | 99.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -1643.9% | -9321.9% |
| — | -12.9% | -0.5% | -0.4% | 0.0% | 0.0% | 0.0% | +106.1% | +101.1% | +102.0% | +100.6% | +95.7% | -9421.9% | |
| Operating Margin | -2334.2% | -173.5% | -269.8% | -390.1% | -919.0% | -1314.3% | -9487.4% | -237990.0% | -61430.9% | -97726.8% | -207670.7% | -30994.4% | -115368.5% |
| — | +86.8% | +97.2% | +99.8% | +98.5% | +98.7% | +95.4% | -667.8% | +46.8% | -27.0% | +8.7% | +95.5% | -467.6% | |
| Net Margin | -2804.8% | -209.8% | -350.3% | -784.9% | -783.4% | -1404.0% | -12852.3% | -335272.5% | -167907.9% | -116563.4% | -336290.2% | -32317.5% | -148239.7% |
| — | +85.1% | +97.3% | +99.8% | +99.5% | +98.8% | +96.2% | -937.4% | -13.3% | -24.0% | -24.4% | +95.6% | -533.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -93.2% | — | -26.2% | -37.8% | -15.8% | -21.2% | -31.8% | -29.6% | -49.8% | -26.4% | -43.5% | -33.0% | -30.3% |
| — | — | +17.7% | -27.4% | +68.2% | +19.8% | +26.7% | +10.1% | -64.7% | +20.2% | -62.5% | -37.6% | -13.3% | |
| ROIC | — | — | — | — | — | — | — | — | -3209.3% | -46.4% | -46.2% | -53.1% | -31.8% |
| — | — | — | — | — | — | — | — | -10001.1% | -56.6% | -109.8% | -96.0% | +16.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.36 | — | 4.11 | 2.22 | 3.36 | 2.68 | 3.91 | 3.64 | 5.05 | 2.38 | 0.11 | 0.20 | 0.28 |
| — | — | +5.1% | -39.1% | -33.4% | +12.4% | +3489.2% | +1712.4% | +1697.8% | +17.9% | -64.4% | -64.0% | -69.0% | |
| Quick Ratio | 3.21 | — | 3.98 | 2.05 | 3.21 | 2.64 | 3.88 | 3.64 | 5.05 | 2.38 | 0.11 | 0.20 | 0.28 |
| — | — | +2.5% | -43.8% | -36.4% | +11.0% | +3462.5% | +1712.4% | +1697.8% | +36.9% | -64.4% | -61.8% | -69.0% | |
| Interest Coverage | -2.61 | -2.02 | -2.47 | -2.23 | -4.66 | -1.99 | -2.55 | -2.54 | -2.66 | -2.29 | -2.64 | -3.78 | -2.95 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 42 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonImmunityBio, Inc.'s current P/E is -15.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ImmunityBio, Inc.'s current operating margin is -2334.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ImmunityBio, Inc.'s business trajectory between earnings reports.